Caricamento...
A cost–utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer
BACKGROUND: Despite initial promising results, the IMvigor211 clinical trial failed to demonstrate an overall survival (os) benefit for atezolizumab compared with chemotherapy as second-line treatment for metastatic bladder cancer (mbc). However, given lessened adverse events (aes) and preserved qua...
Salvato in:
| Pubblicato in: | Curr Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Multimed Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467791/ https://ncbi.nlm.nih.gov/pubmed/32905260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5459 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|